Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Free Cash Flow: 2009-2024

Historic Free Cash Flow for Madrigal Pharmaceuticals (MDGL) over the last 16 years, with Dec 2024 value amounting to -$457.0 million.

  • Madrigal Pharmaceuticals' Free Cash Flow rose 216.57% to $79.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$161.6 million, marking a year-over-year increase of 62.70%. This contributed to the annual value of -$457.0 million for FY2024, which is 40.32% down from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Free Cash Flow of -$457.0 million as of FY2024, which was down 40.32% from -$325.7 million recorded in FY2023.
  • Madrigal Pharmaceuticals' 5-year Free Cash Flow high stood at -$157.9 million for FY2020, and its period low was -$457.0 million during FY2024.
  • Moreover, its 3-year median value for Free Cash Flow was -$325.7 million (2023), whereas its average is -$335.9 million.
  • Data for Madrigal Pharmaceuticals' Free Cash Flow shows a maximum YoY crashed of 271.33% (in 2020) over the last 5 years.
  • Madrigal Pharmaceuticals' Free Cash Flow (Yearly) stood at -$157.9 million in 2020, then decreased by 16.61% to -$184.1 million in 2021, then dropped by 22.24% to -$225.1 million in 2022, then slumped by 44.71% to -$325.7 million in 2023, then tumbled by 40.32% to -$457.0 million in 2024.